Stock Ratings / Health Care / ACRS / financials

CLYM (38) CRMD (62) NGNE (36) IRWD (69) ⌘ Pro Terminal →

Aclaris Therapeutics Inc. (ACRS) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$3.99 +0.76% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $3.99

Aclaris Therapeutics Inc. (ACRS) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE E • RED ALERT Cap $587.3M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $3.99 (-0.05%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (31/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-

Each axis scored 0–20

12M PRICE TARGET CONE-12% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ACRS)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (31/100 Composite)

🔍 WHY ACRS SCORES 31/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (39% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+10/20 pts (32% of score)

FRED Regime × Technicals: 42% of 52W Range • RSI-14 at 45.5 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$3.83-14.4% Next Q

Q2 (-2Q)

Grade E$3.28+14.3% Next Q

Q3 (-1Q)

Grade E$3.75+6.4% Next Q

Current

Grade E$3.99-9.4% Hist 90D α

Trajectory: E (23) → E (31)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a ACRS Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While ACRS currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.88) and Max Pain ($4.19) forces dealer call-delta covering toward $6.93.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ACRS• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “ACRS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 31%NO 69%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How ACRS Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $31.2M

FY24

Rev $18.7M

FY25

Rev $7.8M

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$7.8M	73.3%	-80%	-$64.9M	-$47.2M	-45%
FY 2024	$18.7M	85.1%	-80%	-$132.1M	-$20.2M	-45%
FY 2023	$31.2M	73.3%	-80%	-$88.5M	-$78.3M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ACRS)

✓Walkthrough of ACRS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

ACRS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -8.06%📐 HORIZONTAL RANGE

2026-10-30O $4.00H $4.07L $3.87C $3.99VOL 1.88M

RES: $7.99SUP: $3.01SMA50: $4.88SMA200: $4.53

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ACRS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 ACRS Butterfly Map → + Track ACRS →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -58.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ACRS today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for ACRS. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for ACRS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ACRS)

Health Care Rank #914 of 1016 ⚔️ CLYM vs ACRS Full Matrix →

1. Head-to-Head Health Care Peer Comparison (ACRS vs. CLYM, CRMD, NGNE, IRWD)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Aclaris Therapeutics Inc. (ACRS) ranks #914 by composite RQD confidence (31/100, grade E) and #424 by equity capitalization ($587.3M). Within this direct 5-issuer industry benchmark cohort, CRMD leads on earnings valuation at 3.7x trailing P/E, while IRWD leads on capital efficiency and profitability with 85.0% ROIC and — gross margin. IRWD currently holds the highest overall quantitative score in the immediate peer group at 69/100 (C+) compared with ACRS at 31/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
ACRS ACTIVE Aclaris Therapeutics Inc.	E	31/100	—	73.3%	-35.0%	+0.76%	$587.3M	Benchmark Subject
CLYM Climb Bio Inc.	D-	38/100	—	—	-35.0%	+2.08%	$593.3M	/clym-vs-acrs →
CRMD CorMedix Inc.	C	62/100	3.7x	88.5%	45.5%	-6.83%	$595.5M	/crmd-vs-acrs →
NGNE Neurogene Inc.	D-	36/100	—	—	-35.0%	-5.26%	$576.7M	/ngne-vs-acrs →
IRWD Ironwood Pharmaceuticals Inc. (Class A)	C+	69/100	24.9x	—	85.0%	+0.28%	$598.2M	/irwd-vs-acrs →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001557746

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aclaris Therapeutics Inc. (ACRS) reported GAAP revenue of $7.8M (-58.2% vs. FY2024 revenue of $18.7M , and -75.0% cumulative change since FY2023) , GAAP net income of -$64.9M, operating cash flow of -$47.1M, and free cash flow of -$47.2M (-133.8% YoY). On the balance sheet, ACRS closed FY2025 with $160.5M in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$7.8M	-$64.9M	-$47.1M	-$47.2M	$160.5M	—
FY2024 (FY)	2024-12-31	$18.7M	-$132.1M	-$20.1M	-$20.2M	$220.3M	—
FY2023 (FY)	2023-12-31	$31.2M	-$88.5M	-$78.3M	-$78.3M	—	—

3. ACRS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ACRS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Aclaris Therapeutics Inc. (NASDAQ: ACRS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $3.99 (+0.76% 1D, market cap $587.3M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ACRS ranks #914 in composite RQD confidence.

How does ACRS compare to CLYM and CRMD in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ACRS carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 73.3%, and ROIC of -35.0%. By comparison, CLYM (Climb Bio Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $593.3M) and CRMD (CorMedix Inc.) posts a C grade (62/100 RQD, P/E 3.7x, ROIC 45.5%, cap $595.5M). Among the 5-stock peer group, CRMD leads on earnings multiple (3.7x) while IRWD leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ACRS?

Per ACRS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001557746), Aclaris Therapeutics Inc. generated $7.8M in revenue (-58.2% YoY), -$64.9M in net income, and -$47.2M in free cash flow against $160.5M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ACRS trading relative to its 50-day, 200-day, and 52-week technical levels?

ACRS last traded at $3.99 (+0.76% on volume of 1,458,849 shares), positioning the stock -18.24% below its 50-day simple moving average ($4.88) and -11.92% below its 200-day simple moving average ($4.53). Across its 52-week range of $2.10 to $6.60, ACRS sits at the 42.0% percentile with a 14-day RSI of 45.5 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($3.49 to $4.49).

ACRS Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

How profitable is Aclaris Therapeutics Inc. (ACRS)?

In FY 2025 (10-K), ACRS converted $7.8M of revenue into a 73.3% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Direct Sub-Reports: ACRS RQD Cockpit ACRS 12M Forecast ACRS Earnings & Move ACRS Dividends & DRIP ACRS Insiders & 13F ACRS Whale Options ACRS Profit Sankey ACRS News & Why